Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

ATM (ATM serine/threonine kinase)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FoundationOne® CDx (110)

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

TruSeq®Amplicon - Cancer Panel (5)

Guardant360 TissueNext™ (2)

UW-Oncoplex™ (2)

Vysis CLL FISH Probe Kit (2)

Tempus xT Assay (1)

AmoyDx® HANDLE HRR NGS Panel

AmoyDx® HRD Complete Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® VariantPlex® Solid Tumor Kit

Archer™ VARIANTPlex™ Lymphoma panel

Aventa FusionPlus Test

BROCA Cancer Risk Panel

Blueprint Genetics Comprehensive Hereditary Cancer Panel

CancerNext-Expanded®

CustomNext-Cancer®

Devyser HBOC NGS

Empower™ Hereditary cancer test

GALEAS™ Hereditary Plus

Invitae Common Hereditary Cancers Panel

Labcorp® Plasma Complete™

Myriad myRisk® Hereditary Cancer

NeXT Dx™ Test

Neo Comprehensive - Myeloid Disorders Assay

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ PARPi CDx

OncoGuide™ NCC Oncopanel System

OncoPanel™ Assay

Oncomine Tumor Mutation Load Assay

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio® plasma focus™ Dx

PGDx elio™ plasma resolve assay

PredicineCARE™

PredicineHEME™

SOPHiA DDM HRD Solution

StrataNGS™ Test

SureSeq CLL + CNV V3 NGS Panel

SureSeq™ CLL + CNV Panel

Tempus xF Assay

Tempus xF+ Panel

TheraSure™-CNI MONITOR Assay

Theralink Assay

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

FoundationOne® CDx (110)

Guardant360® CDx (54)

FoundationOne® Liquid CDx (21)

TruSeq®Amplicon - Cancer Panel (5)

Guardant360 TissueNext™ (2)

UW-Oncoplex™ (2)

Vysis CLL FISH Probe Kit (2)

Tempus xT Assay (1)

AmoyDx® HANDLE HRR NGS Panel

AmoyDx® HRD Complete Panel

AnchorAIM® 72 gene detection for individualized treatment of solid tumors

Archer® VariantPlex® Solid Tumor Kit

Archer™ VARIANTPlex™ Lymphoma panel

Aventa FusionPlus Test

BROCA Cancer Risk Panel

Blueprint Genetics Comprehensive Hereditary Cancer Panel

CancerNext-Expanded®

CustomNext-Cancer®

Devyser HBOC NGS

Empower™ Hereditary cancer test

GALEAS™ Hereditary Plus

Invitae Common Hereditary Cancers Panel

Labcorp® Plasma Complete™

Myriad myRisk® Hereditary Cancer

NeXT Dx™ Test

Neo Comprehensive - Myeloid Disorders Assay

NeoTYPE® Lung Tumor Profile

Northstar Select™

NovoFocus™ PARPi CDx

OncoGuide™ NCC Oncopanel System

OncoPanel™ Assay

Oncomine Tumor Mutation Load Assay

OptiSeq™ Pan-Cancer Gene Panel

PGDx elio® plasma focus™ Dx

PGDx elio™ plasma resolve assay

PredicineCARE™

PredicineHEME™

SOPHiA DDM HRD Solution

StrataNGS™ Test

SureSeq CLL + CNV V3 NGS Panel

SureSeq™ CLL + CNV Panel

Tempus xF Assay

Tempus xF+ Panel

TheraSure™-CNI MONITOR Assay

Theralink Assay

TruSight Oncology Comprehensive

TruSight Tumor 170 Assay

VarMap™ Pan-Cancer NGS Panel

oncoReveal™ Core LBx

oncoReveal™ Essential LBx

oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel

›

ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
ATM mutation	Squamous Cell Carcinoma of Head and Neck	ATM mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
ATM positive	Prostate Cancer	ATM positive	Prostate Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
ATM mutation	Chronic Lymphocytic Leukemia	ATM mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
ATM mutation	Ovarian Cancer	ATM mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
ATM mutation	Solid Tumor	ATM mutation	Solid Tumor	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B	rucaparib Sensitive: B - Late Trials rucaparib Sensitive : B
ATM mutation	Chronic Lymphocytic Leukemia	ATM mutation	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
ATM mutation	Lung Adenocarcinoma	ATM mutation	Lung Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Pancreatic Cancer	ATM mutation	Pancreatic Cancer	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1